Jacobs Levy Equity Management Inc. Purchases 147,438 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

Jacobs Levy Equity Management Inc. grew its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 35.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 566,328 shares of the biopharmaceutical company's stock after purchasing an additional 147,438 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.90% of MacroGenics worth $1,863,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in MacroGenics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 4,707 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of MacroGenics in the third quarter valued at about $55,000. DRW Securities LLC bought a new position in shares of MacroGenics during the second quarter valued at about $56,000. XML Financial LLC boosted its holdings in MacroGenics by 66.0% during the third quarter. XML Financial LLC now owns 17,600 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 7,000 shares during the last quarter. Finally, K2 Principal Fund L.P. bought a new stake in MacroGenics in the 2nd quarter worth about $63,000. Institutional investors own 96.89% of the company's stock.

Analyst Upgrades and Downgrades

MGNX has been the topic of several recent analyst reports. Evercore ISI raised shares of MacroGenics to a "strong-buy" rating in a research report on Monday, September 16th. StockNews.com upgraded shares of MacroGenics from a "sell" rating to a "buy" rating in a research note on Sunday, November 10th. JMP Securities lowered MacroGenics from an "outperform" rating to a "market perform" rating in a report on Thursday, November 7th. Citigroup lowered their target price on shares of MacroGenics from $16.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, August 15th. Finally, HC Wainwright restated a "neutral" rating and issued a $4.00 target price on shares of MacroGenics in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, MacroGenics currently has an average rating of "Hold" and a consensus price target of $7.63.

MacroGenics Trading Up 3.2 %

Shares of MGNX stock traded up $0.11 during trading hours on Friday, hitting $3.50. 378,723 shares of the company's stock were exchanged, compared to its average volume of 565,422. MacroGenics, Inc. has a 12-month low of $2.95 and a 12-month high of $21.88. The business's 50 day simple moving average is $3.70 and its 200-day simple moving average is $3.93. The company has a market capitalization of $219.66 million, a PE ratio of -2.22 and a beta of 2.04.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.